How to select patients requiring coronary revascularisation using coronary physiology

Bhavik Modi and Divaka Perera

Abstract
The coronary angiogram is an indicator of flow limiting coronary artery disease but coronary physiology at the time of angiography is vital in assessing the true functional significance of coronary artery disease. With advances in guidewire technology and the greater use of physiology within the catheter laboratory, there is now a slow evolution of physiological indices in being able to reliably assess the functional significance of individual lesions and also the adequacy of revascularization in a growing range of clinical scenarios. As co-registration of physiology with the angiogram and intravascular imaging will become easier, we will find ourselves increasingly in an era of ‘Precision PCI’.

Keywords
Catheter-based coronary interventions, stents, chronic ischemic heart disease, acute coronary syndromes

Introduction
The angiogram has been considered the gold standard in detecting coronary artery disease for the last five decades. The underlying principle is lumenography, which has several limitations, not least the fact that it is a 2-dimensional representation of a 3-dimensional structure with the same stenosis appearing markedly different in different planes. Furthermore, identifying the severity of a narrowing on angiography relies on identifying an accurate vessel reference diameter, which is prone to error especially when there is diffuse atheroma throughout a vessel. Although newer techniques have been developed to assess vessel anatomy in greater detail, such as intravascular ultrasound (IVUS) and Optical Coherence Tomography (OCT), inferring the functional impact of a stenosis based on its structure is complex. Several factors influence the haemodynamic changes within a diseased coronary artery, not just the stenosis diameter. These include the length of a stenosis, stenosis geometry and flow velocity within the vessel; which in turn depends on the state of the microvasculature and the amount of myocardium subtended by the stenotic vessel in question (Figure 1). In this article, we review the techniques available for assessing coronary physiology at the time of angiography and the practical applications as well as inherent limitations of each.

Fractional flow reserve
The pressure gradient across a stenosis (ratio of distal coronary to aortic pressure, \( \frac{P_d}{P_a} \)) during maximal adenosine-induced hyperaemia is referred to as Fractional Flow Reserve (FFR) and is the most widely used marker of the functional significance of coronary artery disease. During conditions of hyperaemia, coronary autoregulation is temporarily disabled and flow in the distal vessel is assumed proportional to the change in pressure across it. FFR was initially validated nearly three decades ago, against non-invasive surrogate markers of ischaemia in the setting of stable angina. These early
studies suggested that a binary FFR threshold of 0.75 accurately identifies patients who have an abnormal non-invasive ischaemia test and that it is safe to defer intervention on vessels associated with a FFR value higher than this threshold. It has since also been shown that the visual assessment of angiographic stenosis severity does not reliably correlate with physiological assessment, leading to a misclassification of stenoses in around a third of lesions.\textsuperscript{5,6} Perhaps as a consequence, a body of evidence has accumulated that FFR-guided revascularisation confers significant clinical and prognostic benefit over management based on angiography alone, particularly for stable angina,\textsuperscript{7-10} and potentially managing non-culprit vessels in NSTEMI settings.\textsuperscript{11}

**Resting physiological indices**

Despite the evidence for physiology guided management of coronary disease, the uptake has been limited, with many patients being put forward for percutaneous or surgical revascularisation based on angiographic appearances alone. While there are many behavioural and fiscal explanations for this, one potential factor is the perceived complexity of physiological assessment in the cardiac catheter laboratory. In view of this, there has been growing interest in techniques that are based on resting pressure measurement alone, without the need for induction of hyperaemia (collectively referred to as non-hyperemic pressure ratios, NHPR): summarised in Figure 2.

Currently, the most widely used NHPR is the instantaneous wave-free ratio (iFR). iFR is defined as $P_d/P_a$ ratio during the latter 75% of diastole (minus the last 5ms), when resistance is purported to be constant and pressure can be assumed proportional to flow, without the need to modulate resistance with adenosine-induced hyperaemia. iFR-guided management has recently been shown to have comparable investigator determined revascularisation rates to FFR, in a relatively low-risk group of patients, with data awaited on more complex subsets.\textsuperscript{12,13} The design and conclusion of these studies has drawn some criticism. The data for iFR is driven by the DEFINE-FLAIR and iFR-SWEDHEART trials, which were non-inferiority trials with a non-inferiority margin that has been suggested to be generous. A pooled meta-analysis subsequently suggested a numeric excess of death and MI events occurred in the iFR group (albeit statistically non-significant ($p = 0.09$)).\textsuperscript{14} In addition, there is growing evidence to suggest the wave-free period is not associated with a fixed minimal microvascular resistance with NHPR indices showing greater test-retest variability.\textsuperscript{15} Furthermore, there now good evidence that there is actually no significant difference between iFR and other NHPR indices, such a resting $P_d/P_a$ or Resting Flow Ratio (RFR), both numerically and with respect to their agreement with FFR.\textsuperscript{16} In our opinion, NHPR

\begin{align*}
\text{Figure 1.} & \quad \text{Pressure gradients across a stenosis can be described by a quadratic relationship between pressure and flow that involve the energy losses due to the flow separation within a vessel ($s$) and the unique frictional coefficient ($f$) of a stenosis. This takes the form of $\Delta P = fQ + sQ^2$, in which $\Delta P$ indicates change in pressure, $f$ indicates the frictional coefficient of a lesion (influenced by lesion length and diameter stenosis), $s$ indicates the separation coefficient of flow conditions in a vessel, and $Q$ indicates flow.}
\end{align*}

\begin{align*}
\text{Figure 2.} & \quad \text{Four commonly used Non-Hyperemic Pressures Ratios (NHPR): Resting $P_d/P_a$, RFR, iFR and DFR. The Red line represents the aortic pressure, the green line the distal coronary pressure and the gray shaded area represents the measurement period.}
\end{align*}
indices are similar to each other, all share the relative ease afforded by not needing to induce hyperaemia but by the same token, are similarly limited in accuracy.

**Threshold creep**
Mounting evidence suggests that patients on optimal medical therapy alone have an excellent prognosis, as suggested by the COURAGE trial and more recently the ISCHEMIA trial. On the other hand, physiology-guided revascularization, is associated with improved outcomes, with data now existing out to 5 years from the original FAME studies. Data also exists to suggest patients with a lower FFR are most likely to derive prognostic and symptomatic benefit.

The initial derivation studies of FFR were performed against a combination of non-invasive tests and showed an optimum threshold of 0.75 to identify ischaemia. The first randomized trial to show improved outcomes with revascularization guided by FFR also used a threshold of 0.75. Subsequent RCT's to investigating whether there are improved clinical outcomes with FFR guided revascularisation were done using the higher threshold of 0.80 in the FAME trials (giving the “safety net” of the greater negative predictive value at the 0.80 threshold). Following this, iFR was also originally derived and validated against an FFR threshold of 0.8. Despite this, again a “safety net” of a higher 0.89 threshold was used for the iFR-Swedeheart and DEFINE-Flair trials.

This ‘upward creep’ of contemporary thresholds may have resulted in suboptimal diagnostic accuracy compared to an FFR threshold of 0.75 and iFR threshold of 0.86 (cut-offs in original derivation studies). Whether patients would derive greater benefit if physiology guided revascularisation was guided by the more stringent original thresholds remains to be seen.

**Physiology in special scenarios: LMCA disease**
Whilst evidence supporting physiology-guided revascularization has grown in recent years, most of the trials such as DEFER and the FAME have excluded LMCA disease. This is despite the fact that the LMCA is even more prone to angiographic error compared to the vessels to angulation and overlap. There are some observational data that suggests FFR guided LMCA revascularization is safe but the individual studies were small, incorporated different thresholds and different modes of revascularization.

Practically assessing the functional significance of LMCA disease is slightly more complex than downstream single vessel disease. Firstly, there are technical challenges with the need to disengage the guide catheter and equalise in the aortic root. This also means there is a need for intravenous adenosine as opposed to intracoronary adenosine. Once FFR is measured, there is the issue of serial coronary artery disease with downstream disease in the LAD and/or LCx found in the majority of cases. Numerous data suggest significant error (usually in the form of underestimation) in identifying the true stenosis significance in the presence of serial downstream coronary artery disease. As a result, it is recommended that when a LMCA stenosis is assessed physiologically, this should be done with guidance from a pressure wire pullback from both the LCx and LAD (Figure 3).

When a left main stenosis is found in the presence of a physiologically disease-free side branch, there is evidence from animal studies, with human validation, to suggest the true LMCA stenosis can be isolated by measuring into the disease-free vessel (Figure 3). Whilst small errors are still possible with this method, the error is only most marked when the FFR in the serially diseased vessel is <0.45. When there is downstream disease in both vessels, physiological assessment of true LMCA significance becomes more of a challenge. In the

![Figure 3](image-url)
Physiology in special scenarios: Serial disease

The data supporting physiology-guided revascularisation are largely derived from studies that only included vessels with single discrete lesions. The reality, particularly within elderly and diabetic populations, is that serial and diffuse CAD is common. As discussed in the section on physiological assessment of LMCA disease, it is unclear if physiological indices can reliably assess individual lesions in the commonly-encountered scenario of serial/diffuse coronary artery disease, with significant stenosis underestimation having been shown, even when relying on a pressure wire pullback method (Figure 2).

It has been purported that resting physiological indices, such as iFR, are associated with less serial stenosis interaction but data now exists to suggest all pressure-derived indices, resting and hyperaemic, are prone to significant error and stenosis misclassification, perhaps with resting indices only marginally less so. To correct for some of this error, a simple equation to use with hyperemic pressure wire pullback has been derived with a 3-D printed model and validated in patients with serial disease to show a significant reduction error and stenosis misclassification.32,33

Until novel FFR/iFR correction equations are studied further, we recommend making decisions based on the size of the step-up observed during hyperemic or resting pressure wire pullback manoeuvres, both before and after PCI. The pullback should be done at a steady speed from the distal vessel, without stopping between stenoses, and should be performed even when a stenosis appears angiographically discrete, as there maybe be accompanying diffuse disease in the vessel that would affect the pressure gradient across a given stenosis. The pullback should be done with knowledge that the accompanying disease is most commonly underestimated, and the extent of this underestimation is greater when there is a large cumulative pressure drop in the vessel.32

Physiology in special scenarios: Acute coronary syndromes

FFR has largely been validated for use in the stable coronary disease and its applicability in the acute setting is less clear. In the case of ST-elevation myocardial infarction (STEMI), impaired microcirculation in the infarction region has been shown to influence FFR measurements in the culprit vessel for up to 6 months after the event. However, FFR has been used to guide revascularisation in non-culprit vessels with some data to suggest a better outcome than angiographically-guided revascularisation, although definitive data is awaited on this with ongoing trials.

In the NSTEMI setting, in the absence of clear microcirculatory impairment and heavy thrombus load, FFR measurements performed during angiography can be useful to guide revascularization. Decisions about deferral of revascularisation, however, might need to be made more cautiously for these patients with some evidence to suggest higher FFR thresholds may be safer for deferral in the ACS setting.

Physiology in other special scenarios

Vein grafts

There are limited data on FFR measurements in stenotic bypass vessels. A non-randomised study has shown that an FFR-guided PCI strategy of intermediate bypass graft stenoses resulted in lower MACE rates compared to an angiographic-guided strategy, but this study is hypothesis generating only and these patients were excluded from the major trials, such as FAME. In summary, FFR assessment of bypass grafts should be done with caution and stenoses of downstream native vessels should be considered native serial stenoses, with the same caveats applicable.

Chronic total occlusions

When a donor vessel supplies a chronic total coronary occlusion (CTO), the FFR and iFR in that vessel should be interpreted with caution as it takes into account the total burden of disease (not just in the donor vessel, but also the viable territory supplied by the CTO vessel). This is supported by data to show that upon successful PCI of the CTO, the donor vessel FFR and iFR show an immediate and sustained increase.

Aortic stenosis

Patients with significant aortic stenosis were excluded from the major coronary physiology trials such as
FAME and FAME-2.7,8 The reliability of physiological indices is still not established for severe Aortic Stenosis, despite recent data shedding light on the haemodynamic implications of severe aortic stenosis.41,42 Overall, recent data demonstrate that FFR-guided revascularization is feasible and safe, and results in deferral of unnecessary stenting in a large proportion of patients with Aortic Stenosis.43 but FFR should be interpreted cautiously in this group of patients with heterogenous responses to adenosine and variable microvascular dysfunction.

LV dysfunction
Reduced Ejection Fraction has been shown in subgroup analyses of the FAME trial to have no significant influence on FFR, unless the stenosis is very tight (FFR < 0.6), in which case clinical overestimation might occur.44 This subset of patients does however often have elevated right atrial pressures. Right atrial pressure measurement originally formed part of the FFR calculation, but for the purpose of simplicity, is assumed to be zero. It has however been shown in a small cohort study that ignoring venous pressures (or assuming an arbitrary fixed value such as 5 or 10 mmHg) results in significant errors in FFR measurement, especially at lower values of Pd and hence FFR.45 While FFR-guided revascularisation has been shown to be valid in patients with LV dysfunction, this is another sub-group where it should be interpreted cautiously.

Assessing the adequacy of revascularisation with physiology
Coronary physiology is used even less by operators to detect the adequacy of revascularisation. This is despite the fact that we have known for a while that low FFR after PCI in an angiographically optimised vessel portends a worsened prognosis.46 Sub-optimal Post-PCI FFR and iFR have both been subsequently shown to be associated with worse outcomes, although recent data suggests that compared with post-PCI FFR, post-PCI Pd/Pa shows limited reclassification ability for the occurrence of TVF.47

The DEFINE-PCI study showed that post-PCI physiological assessment detected residual ischemia in nearly 1 in 4 patients after coronary stenting despite an operator-determined angiographically successful result,48 with recently presented 1-year data from this study suggesting patients with residual ischaemia were more symptomatic (TCT Connect 2020, yet to be published). Data from the TARGET-FFR study was also recently presented at TCT Connect 2020, which showed that sub-optimal results after angiography-guided PCI are common and checking physiology post PCI results in fewer patients leaving the catheter laboratory with an FFR<0.80.

Future directions in coronary physiology
We believe the next 10 years will see coronary physiology evolve in several ways. Firstly, despite the evidence to support physiology guided revascularisation, the perceived ‘extra-step’ often prevents clinicians from using physiology, particularly in developing countries. There is now an increased effort from manufacturers to develop pressure wires that perform equivalently to standard workhorse guidewires. An example is the COMET II from Boston Scientific which has been developed with Asahi to encourage angioplasty on the same wire after physiological assessment.

Another advance that is being made is the improvements in co-registration of physiology in the catheter laboratory. As well as co-registration of physiology with the angiogram, there is an increasing drive to co-register physiological data with intravascular imaging. An exciting co-registration tool currently in development is Optical Coherence Tomography (OCT) derived FFR (so called ‘OFR’) – this potentially has the advantage of being able to do physiological and anatomical assessment of a vessel on a standard workhorse guidewire. Data for the latest iteration of OFR suggests it substantially improved the accuracy in identifying hemodynamically significant lesions compared with OCT alone. The study reported that the area under the curve was 0.93 for OFR and 0.80 for OCT-derived MLA.49 Whilst this is a developing tool with further data awaited, what we have currently available to clinicians is Philips developed ‘iFR and IVUS tri-registration’ that enables IVUS and iFR pullback data to be co-registered onto the angiogram (see Figure 4).
Whilst Philips and iFR have led the way, other physiological and intravascular imaging tools will catch up over the next decade with an era of ‘Precision PCI’ awaiting us.

In addition to guidewire and co-registration advances, there is also a move towards being able to diagnose microvascular coronary artery disease in the catheter laboratory as easily as diagnosing flow-limiting epicardial coronary artery disease, with potential therapies being studied.\textsuperscript{50,51} With the use of thermodilution boluses on a standard pressure wire, clinicians can measure the Index of Microvascular Resistance (IMR = Pd × mean transit time of room temperature saline during maximal hyperaemia) and Coronary Flow Reserve (CFR = coronary flow in hyperaemia/coronary flow at rest). An in-depth discussion of advances in microvascular coronary physiology is beyond the scope of this review but is certainly a growing field and can no longer be ignored by clinicians.

Conclusions

The coronary angiogram is a useful indicator of flow limiting coronary artery disease but coronary physiology at the time of angiography is vital in assessing the true functional significance of coronary artery disease. With the greater use of physiology within the catheter laboratory, there is now a slow evolution of physiological indices in being able to reliably assess the functional significance of individual lesions and also the adequacy of revascularization in a growing range of clinical scenarios.

As we move towards an era of precision PCI, co-registration of physiology with the angiogram and intravascular imaging will become common and with improvements in pressure-wire technology, clinicians will find it easier to physiologically optimise their PCI outcomes.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Ethical approval

No ethical approval was needed or sought to write this article.

Guarantor

DP.

Contributorship

Both authors have contributed to the writing and editing of this manuscript.

ORCID iD

Bhavik Modi  https://orcid.org/0000-0002-9413-8291

References

1. Modi BN, Silva KD, Rajani R, et al. Physiology-guided management of serial coronary artery disease: a review. \textit{JAMA Cardiol} 2018; 3: 432–438.
2. Gould KL, Lipscomb K and Hamilton GW. Physiologic basis for assessing critical coronary stenosis. \textit{Am J Cardiol} 1974; 33: 87–94.
3. Pijs NH, Son JA van, Kirkeeide RL, et al. Experimental basis of determining maximum coronary, myocardial, and collateral blood flow by pressure measurements for assessing functional stenosis severity before and after percutaneous transluminal coronary angioplasty. \textit{Circulation} 1993; 87: 1354–1367.
4. Pijs NHJ, Bruyne BD, Peels K, et al. Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses. \textit{N Engl J Med} 1996; 334: 1703–1708.
5. Toth G, Hamilos M, Pyxaras S, et al. Evolving concepts of angiogram: fractional flow reserve discordances in 4000 coronary stenoses. \textit{Eur Heart J} 2014; 35: 2831–2838.
6. Curzen N, Rana O, Nicholas Z, et al. Does routine pressure wire assessment influence management strategy at coronary angiography for diagnosis of chest pain? The RIPCORD study. \textit{Circulation} 2014; 7: 248–255.
7. Bech GJW, Bruyne BD, Pijs NHJ, et al. Fractional flow reserve to determine the appropriateness of angioplasty in moderate coronary stenosis: a randomized trial. \textit{Circulation} 2001; 103: 2928–2934.
8. Xaplanteris P, Fournier S, Pijs NHJ, et al. Five-year outcomes with PCI guided by fractional flow reserve. \textit{N Engl J Med} 2018; 379: 250–259.
9. Tonino PAL, Bruyne BD, Pijs NHJ, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. \textit{N Engl J Med} 2009; 360: 213–224.
10. Bruyne BD, Fearon WF, Pijs NHJ, et al. Fractional flow reserve-guided PCI for stable coronary artery disease. \textit{N Engl J Med} 2014; 371: 1208–1217.
11. Berry C, Corcoran D, Hennigan B, et al. Fractional flow reserve-guided management in stable coronary disease and acute myocardial infarction: recent developments. \textit{Eur Heart J} 2015; 36: 3155-3164.
12. Göteborg M, Christiansen EH, Gudmundsdottir IJ, et al. Instantaneous wave-free ratio versus fractional flow reserve to guide PCI. \textit{N Engl J Med} 2017; 376:1813–1823.
13. Davies JE, Sen S, Dehbi H-M, et al. Use of the instantaneous wave-free ratio or fractional flow reserve in PCI. \textit{N Engl J Med} 2017; 376: 1824–1834.
14. Berry C, McClure JD and Oldroyd KG. Meta-analysis of death and myocardial infarction in the DEFINE-FLAIR and iFR-SWEDEHEART Trials. \textit{Circulation (Baltimore)} 2017; 136: 2389–2391.
15. Johnson NP, Johnson DT, Kirkeeide RL, et al. Repeatability of fractional flow reserve despite variations in systemic and coronary hemodynamics. *JACC Cardiovascular Interventions* 2015; 8: 1018–1027.

16. van’t Veer M, Pijs NHJ, Henningan B, et al. Comparison of different diastolic resting indexes to iFR: are they all equal? *J Am Coll Cardiol* 2017; 70: 3088–3096.

17. Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. *N Engl J Med.* 2007; 356: 1503–1516.

18. Johnson NP, Toth GG, Lai D, et al. Prognostic value of fractional flow reserve: linking physiologic severity to clinical outcomes. *J Am Coll Cardiol* 2014; 64: 1641–1654.

19. Bruyne BD, Pijs NHJ, Kalesan B, et al. Fractional flow reserve–guided PCI versus medical therapy in stable coronary disease. *N Engl J Med* 2012; 367: 991–1001.

20. Sen S, Escaned J, Malik IS, et al. Development and validation of a new adenosine-independent index of stenosis severity from coronary wave-intensity analysis. *J Am Coll Cardiol* 2012; 59: 1392–1402.

21. Sen S, Asrress KN, Nijjer S, et al. Diagnostic classification of the instantaneous wave-free ratio is equivalent to fractional flow reserve and is not improved with adenosine administration. Results of CLARIFY (classification accuracy of pressure-only ratios against indices using flow study). *J Am Coll Cardiol* 2013; 61: 1409–1420.

22. Modi BN, Rahman H, Kaier T, et al. Revisiting the optimal fractional flow reserve and instantaneous wave-free ratio thresholds for predicting the physiological significance of coronary artery disease. *Circulation* 2018; 11: e007041.

23. Modi B, Hoef T, Piek J, et al. Physiological assessment of left main coronary artery disease. *EuroIntervention* 2017; 13: 820–827.

24. Lindstaedt M, Spiecker M, Perings C, et al. How good are experienced interventional cardiologists at predicting the functional significance of intermediate or equivocal left main coronary artery stenoses? *Int J Cardiol* 2007; 120: 254–261.

25. Mallidi J, Atreya AR, Cook J, et al. Long-term outcomes following fractional flow reserve-guided treatment of angiographically ambiguous left main coronary artery disease: a meta-analysis of prospective cohort studies. *Catheter Cardiovasc Interv* 2015;86(1):12–8.

26. Fearon WF, Yong AS, Lenders G, et al. The impact of downstream coronary stenosis on fractional flow reserve assessment of intermediate left main coronary artery disease: human validation. *JACC Cardiovascular Interventions* 2015; 8: 398–403.

27. Kim H-I, Koo B-K, Nam C-W, et al. Clinical and physiological outcomes of fractional flow reserve-guided percutaneous coronary intervention in patients with serial stenoses within one coronary artery. *JACC Cardiovascular Interventions* 2012; 5: 1013–1018.

28. Jasti V, Ivan E, Yalamanchili V, et al. Correlations between fractional flow reserve and intravascular ultrasound in patients with an ambiguous left main coronary artery stenosis. *Circulation* 2004; 110: 2831–2836.

29. Park S-J, Ahn J-M, Kang S-J, et al. Intravascular ultrasound-derived minimal lumen area criteria for functionally significant left main coronary artery stenosis. *JACC Cardiovascular Interventions* 2014; 7: 868–874.

30. Hernandez JM de la T, Hernandez F, Alfonso F, et al. Prospective application of predefined intravascular ultrasound criteria for revascularization of intermediate left main coronary artery lesions: results from the multicentered litro study. *J Am Coll Cardiol* 2011; 58(4):351–358.

31. Dortimer AC, Shenoy PN, Shiroff RA, et al. Diffuse coronary artery disease in diabetic patients: fact or fiction? *Circulation* 1978; 57: 133–136.

32. Modi BN, Ryan M, Chattersingh A, et al. Optimal application of fractional flow reserve to assess serial coronary artery disease: a 3D-printed experimental study with clinical validation. *J Am Heart Assoc* 2018; 7: e010279.

33. Modi BN, Rahman H, Ryan M, et al. Comparison of fractional flow reserve, instantaneous wave free ratio and a novel technique for assessing coronary arteries with serial lesions. *EuroIntervention* 2019; 16(7): 577–583.

34. Cuculi F, De Maria GL, Meier P, et al. Impact of microvascular obstruction on the assessment of coronary flow reserve, index of microcirculatory resistance, and fractional flow reserve after ST-segment elevation myocardial infarction [published correction appears in J Am Coll Cardiol. 2015 Mar 3;65(8):866. Choudhury, Robin C [Corrected to Choudhury, Robin P]. *J Am Coll Cardiol* 2014; 64: 1894–1904.

35. Puyimarat E, Tabassome S, de Bruyne B, et al. Rationale and design of the flow evaluation to guide revascularization in multivessel ST-elevation myocardial infarction (FLOWER-MI) trial. *Am Heart J* 2020; 222:1–7.

36. Layland J, Oldroyd KG, Curzen N, et al. Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: the British Heart Foundation FAMOUS-NSTEMI randomized trial. *Eur Heart J* 2015; 36: 100–111.

37. Adjeji J, De Bruyne B, Floré V, et al. Significance of intermediate values of fractional flow reserve in patients with coronary artery disease. *Circulation* 2016; 133: 502–508.

38. Di Serafino L, De Bruyne B, Mangiacapra F, et al. Long-term clinical outcome after fractional flow reserve-versus angio-guided percutaneous coronary intervention in patients with intermediate stenosis of coronary artery bypass grafts. *Am Heart J* 2013; 166: 110–118

39. Mohdrazzi SR, Karamasis GV, Al-Janabi F, et al. The impact of coronary chronic total occlusion percutaneous coronary intervention upon donor vessel fractional flow reserve and instantaneous wave-free ratio: Implications for physiology-guided PCI in patients with CTO. *Catheter Cardiovasc Interv* 2018; 92: E139–E148.

40. Karamasis GV, Kalogeropoulos AS, Mohdrazzi SR, et al. Serial fractional flow reserve measurements post coronary chronic total occlusion percutaneous coronary intervention. *Circ Cardiovasc Interv* 2018; 11: e006941.

41. Lumley M, Williams R, Asrress KN, et al. Coronary physiology during exercise and vasodilation in the...
healthy heart and in severe aortic stenosis. *J Am Coll Cardiol* 2016; 68: 688–697.

42. Ahmad Y, Vendrik J, Eftekhari A, et al. Determining the predominant lesion in patients with severe AS and coronary stenoses: a multicenter study using intracoronary pressure and flow. *Circ Cardiovasc Interv* 2019; 12: e008263.

43. Lunardi M, Scarsini R, Venturi G, et al. Physiological versus angiographic guidance for myocardial revascularization in patients undergoing transcatheter aortic valve implantation. *J Am Heart Assoc* 2019; 8: e012618.

44. Kobayashi Y, Tonino PA, De Bruyne B, et al. The impact of left ventricular ejection fraction on fractional flow reserve: insights from the FAME (fractional flow reserve versus angiography for multivessel evaluation) trial. *Int J Cardiol* 2016; 204: 206–210.

45. Perera D, Biggart S, Postema P, et al. Right atrial pressure: can it be ignored when calculating fractional flow reserve and collateral flow index. *J Am Coll Cardiol* 2004; 44: 2089–2091.

46. Pijls NH, Klauss V, Siebert U, et al. Coronary pressure measurement after stenting predicts adverse events at follow-up: a multicenter registry. *Circulation* 2002; 105: 2950–2954.

47. Shin D, Lee SH, Lee JM, et al. Prognostic implications of post-intervention resting Pd/Pa and fractional flow reserve in patients with stent implantation. *J Am Coll Cardiol Interv* 2020; 13: 1920–1933.

48. Jeremias A, Davies JE, Maehara A, et al. Blinded physiological assessment of residual ischemia after successful angiographic percutaneous coronary intervention. *J Am Coll Cardiol Interv* 2019; 12: 1991–2001.

49. Yu W, Huang J, Jia D, et al. Diagnostic accuracy of intracoronary optical coherence tomography-derived fractional flow reserve for assessment of coronary stenosis severity. *EuroIntervention* 2019; 15: 189–197.

50. Rahman H, Corcoran D, Aetesam-Ur-Rahman M, et al. Diagnosis of patients with angina and non-obstructive coronary disease in the catheter laboratory. *Heart (British Cardiac Society)* 2019; 105: 1536–1542.

51. Rahman H, Ryan M, Lumley M, et al. Coronary microvascular dysfunction is associated with myocardial ischemia and abnormal coronary perfusion during exercise. *Circulation* 2019; 140: 1805–1816.